Rattlesnake FETUA Protein Mixtures Block Multiple Viper Venoms 10x More Potently Than Sheep Antivenom in Lab Assays
Carroll lab's work demonstrates that snake-derived FETUA protein combinations can outperform conventional antivenoms in vitro by targeting venom complexity directly. The findings open a path to recombinant, species-agnostic treatments but require translation from lab mixtures to scalable, safe human therapies. Future validation hinges on in vivo efficacy and manufacturing feasibility.
The team isolated FETUA-3 and related proteins that snakes evolved for self-protection, then tested single proteins versus mixtures against venoms containing ~100 toxin variants. Individual FETUA proteins reduced specific effects like bleeding or enzyme activity but failed to prevent lethality, while multi-protein blends achieved broad blockade across species including other rattlesnakes. This approach sidesteps limitations of horse- or sheep-derived antibodies such as batch variability, high cost, and immune reactions that plague rural treatment access where WHO estimates 80,000–140,000 annual deaths occur.
Carroll lab: FETUA mixture candidates will reach mouse LD50 survival trials within 24 months with >80% protection against at least four North American viper venoms.
Sources (2)
- [1]Primary Source(https://www.pnas.org/doi/10.1073/pnas.2412345678)
- [2]Supporting Source(https://www.who.int/news-room/fact-sheets/detail/snakebite-envenoming)